ライフサイエンスコーパス: neutrophil count

1 d-type (WT), primarily driven by an elevated neutrophil count.

2 n alanine transaminase level or decreases in neutrophil count.

3 vels than wild-type mice, presented elevated neutrophil count.

4 uded hyperglycaemia and fever with decreased neutrophil count.

5 s in CD4 cell count, but not by increases in neutrophil count.

6 in cholesterol levels and with reductions in neutrophil counts.

7 protein cholesterol levels and reductions in neutrophil counts.

8 or treatment normalized CXCR4 expression and neutrophil counts.

9 of cotransplanted Tregs exhibited diminished neutrophil counts.

10 t produce mature T cells but maintain normal neutrophil counts.

11 s might contribute to regulating circulating neutrophil counts.

12 had the greatest effects on regulating blood neutrophil counts.

13 h IL-23, but not IL-12, restored circulating neutrophil counts.

14 l counts, and combined sputum eosinophil and neutrophil counts.

15 in the ischemic brain along with the reduced neutrophil counts.

16 these 52 molecules correlated with BAL fluid neutrophil counts.

17 in eosinophil counts and 64% of variation in neutrophil counts.

18 also decreased platelet counts and increased neutrophil counts.

19 lls/L, p = 9.22 x 10(-95)), particularly for neutrophil count (0.174 x [0.158, 0.190]10(9) cells/L, p

20 ts (0.16 x 10(9) cells/L; P = 0.014), higher neutrophil counts (0.11 x 10(9) cells/L; P = 0.026), and

21 nce, 0.89 x 10(9) cells/L; P < 0.001), lower neutrophil counts (0.83 x 10(9) cells/L; P < 0.001), and

22 bin concentration 9 g/dL or higher, absolute neutrophil count 1 x 10(3) cells per mm(3) or higher, an

23 ase 9.6 g/L, 95% CI 7.6-11.6 g/L; p<0.0001), neutrophil counts (1.1x10(9)/L, 0.7-1.5x10(9)/L; p<0.000

24 anaemia (14 [9%] vs 26 [17%]), and decreased neutrophil count (11 [7%] vs 17 [11%]).

25 ression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet count 70,000

26 d grade 3 or 4 adverse events were decreased neutrophil count (14 [39%] of 36 patients in the gemcita

27 common grade 3 or 4 adverse events were low neutrophil count (15 [11%] preoperatively in the chemoth

28 1 [16%] in the CRT only group), low absolute neutrophil count (15 [12%] vs 24 [19%]), fatigue (26 [20

29 in the safety population (n=57) were reduced neutrophil count (15 [26%]), hypophosphatemia (11 [19%])

30 mmon grade 3-4 adverse events were decreased neutrophil count (210 [37%] in the cetuximab group vs 15

31 l neuropathy (25 [6%] vs 12 [3%]), decreased neutrophil count (22 [5%] vs 16 [4%]), and fatigue (17 [

32 spnoea (35 [12%] of 289 patients), decreased neutrophil count (26 [9%]), and fatigue (23 [8%]).

33 t common serious adverse event was decreased neutrophil count: 26 episodes in 14 participants.

34 1 [11%]), dyspnoea (29 [10%]), and decreased neutrophil count (28 [10%]), and with pemetrexed alone w

35 , leucopenia (22 [7%] vs 17 [6%]), decreased neutrophil count (31 [10%] vs 41 [13%]), and decreased w

36 the fixed-dose combination group), decreased neutrophil count (31 [12%] vs 27 [11%]), febrile neutrop

37 ients), leucopenia (42 [16%]), and decreased neutrophil count (40 [15%]); in the placebo plus paclita

38 te blood cell count (11600/microL), absolute neutrophil count (4100/microL), and platelet count (362

39 vacizumab group), and infections with normal neutrophil count (42 events vs 53).

40 ide levels (38 vs 27 ppb, P = .02) and blood neutrophil counts (5.3 vs 4.0 10(9)/L, P </= .001) and s

41 All patients engrafted to an absolute neutrophil count 500/microL at a median of 13 days (rang

42 aemia (138 [29%] vs 47 [20%]), and decreased neutrophil count (57 [12%] vs 19 [8%]).

43 r [2%]) in the nivolumab group and decreased neutrophil count (59 [28%]) in the chemotherapy group.

44 Adjusted HRs comparing neutrophil counts 6 to 7 versus 2 to 3 x 10(9)/l (both w

45 x 1000 cells/muL [IQR, 7.5, 12.9]; P = .01), neutrophil count (6.7 x 1000 cells/muL [IQR, 2.8, 9.7] v

46 t was correlated to the CD66b microparticles/neutrophil count, a surrogate of neutrophil activation a

47 ether age, FEV1 percent predicted, and blood neutrophil counts accurately predict sputum neutrophil p

48 ed granulocyte-colony stimulating factor and neutrophil counts/activity postsuboptimal immunization.

49 d not correlate with outcome, lower absolute neutrophil count after starting concurrent chemoradiothe

50 GP generation correlates closely with airway neutrophil counts after administration of proteases in v

51 Neutrophil counts after trial entry rose significantly m

52 For two traits, lipoprotein(a) levels and neutrophil count, aggregate tests of low-frequency and r

53 137.96+/-0.08 versus 142.71+/-0.07 mm Hg for neutrophil counts; all P<10(-50)).

54 Mean baseline neutrophil counts also varied significantly by genotype:

55 Obesity and high neutrophil counts also worsened the PM effects with or w

56 responses, we found significantly different neutrophil counts among treatments; however, phagocytic

57 bones, a markedly enlarged spleen, elevated neutrophil counts, an enlarged heart, and behavioral hyp

58 bserved dose-dependent increases in absolute neutrophil count (ANC) and absolute lymphocyte count (AL

59 caused a dose-dependent decrease in absolute neutrophil count (ANC) and reduced inflammatory biomarke

60 The median absolute neutrophil count (ANC) at diagnosis was 0.4 x 10(9)/L, a

61 ine neutropenia, 82% of those whose absolute neutrophil count (ANC) decreased by > or = 75% achieved

62 n therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL and platel

63 ivariate and multivariate models of absolute neutrophil count (ANC) nadir and pharmacokinetic paramet

64 teria: positive CSF Gram stain, CSF absolute neutrophil count (ANC) of at least 1000 cells/microL, CS

65 , but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 x 10(9)/L [

66 Median time to recovery of absolute neutrophil count (ANC) was 12 days.

67 commercial G-CSF on the increase of absolute neutrophil counts (ANC).

68 blood with normalization of counts (absolute neutrophil count [ANC]> 1.5 x 10(9)/L, hemoglobin [Hgb]

69 mation (alkaline phosphatase [ALP], absolute neutrophil count [ANC], ferritin [adjusted for iron stat

70 her with laboratory tests (white cell count, neutrophil count and C-reactive protein), and the timing

71 The neutrophil count and leukotriene B4 concentration in bro

72 The association between neutrophil count and microvascular obstruction is abolis

73 The increase in neutrophil count and their priming is mediated by granul

74 ized by a small increase of lymphocyte B and neutrophil counts and a transient drop of total lymphocy

75 of anakinra compared with placebo on airway neutrophil counts and airway proinflammatory cytokine le

76 Profound reductions in neutrophil counts and chemotaxis as well as a diminished

77 y response in the lung as shown by increased neutrophil counts and elevated cytokine and chemokine co

78 an cluster T1, with no differences in sputum neutrophil counts and exhaled nitric oxide and serum IgE

79 , exogenous MCP-1 dose dependently increased neutrophil counts and G-CSF concentrations in the blood.

80 rity was correlated with total leukocyte and neutrophil counts and HCT (P <0.001, P <0.001 and P = 0.

81 iglyceride, VLDL, total WBC, lymphocyte, and neutrophil counts and increase in hsCRP, total cholester

82 white blood cell, lymphocyte, monocyte, and neutrophil counts and increased adiponectin levels witho

83 Adverse events, including low neutrophil counts and increased levels of alanine aminot

84 sociated with reduced bronchoalveolar lavage neutrophil counts and interleukin-6 and macrophage infla

85 Black African participants had lower neutrophil counts and lower circulating concentrations o

86 GER expression correlated with higher sputum neutrophil counts and more severe AHR in COPD patients.

87 ociated TBM and is characterized by high CSF neutrophil counts and Mycobacterium tuberculosis culture

88 clude that efforts should focus on improving neutrophil counts and on treating the frequent and serio

89 in alveolar air spaces, despite normal blood neutrophil counts and survival of emigrated neutrophils,

90 Blood glucose level, total leukocyte count, neutrophil count, and leukocyte labeling efficiency vari

91 (LDH) level, ferritin level, d-dimer level, neutrophil count, and neutrophil-to-lymphocyte ratio wer

92 racy of the white blood cell count, absolute neutrophil count, and platelet count at commonly used th

93 ve protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), specifically

94 ve protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), specifically

95 PET/CT correlated with lung function, sputum neutrophil counts, and CF-CT scores.

96 r peripheral blood eosinophil counts, sputum neutrophil counts, and combined sputum eosinophil and ne

97 older age, lower serum albumin, higher blood neutrophil counts, and greater prevalence of chronic obs

98 y increased proinflammatory IL-1beta levels, neutrophil counts, and IL-17-shifted immunity.

99 tween quintiles of lymphocyte, monocyte, and neutrophil counts, and increased systolic BP, diastolic

100 We also measured interleukin-17A, neutrophil counts, and total protein in bronchoalveolar

101 CXCL10, and interleukin 10 levels; increased neutrophil counts; and decreased T-helper cell type 1 re

102 Neutrophil counts are a ubiquitous measure of inflammati

103 Blood neutrophil counts are determined by the differentiation

104 In the United States, neutrophil counts are lower in black persons than in whi

105 For instance, both eosinophil and neutrophil counts are often increased in the airways of

106 Circulating neutrophil counts are positively regulated by CXCR2 sign

107 a lethal HSV-2 challenge model, we show that neutrophil counts are significantly reduced at 1 and 2 d

108 Neutrophil counts are slightly higher in Mexican-America

109 gen receptor for chemokines null variant for neutrophil count) are generalizable to WBC traits in His

110 d sham groups in the mean increment in blood neutrophil count at 8 hours (6.16 x 10(9)/L and 6.15 x 1

111 this was not the case for sex, indications, neutrophil count at initiation, and concomitant drug tre

112 solation of the ST1 severe strain and higher neutrophil counts at diagnosis in two unrelated large mu

113 Recovery occurred even though blood neutrophil counts began to rise 48 hours after the last

114 ose with the Duffy-null genotype (21%) had a neutrophil count below the threshold often used as a cut

115 OPD), with sputum and bronchoalveolar lavage neutrophil counts broadly correlating with disease sever

116 imulating factor (G-CSF), which can increase neutrophil counts but does not affect cytopenias other t

117 ing was associated with higher leukocyte and neutrophil counts but had a smaller effect among black a

118 rrent chemoradiotherapy exhibit a decline in neutrophil count, but the effects of neutrophils on radi

119 We conclude that IL-17A regulates blood neutrophil counts by inducing G-CSF production mainly in

120 nt inhibition or depletion, depletion of BAL neutrophil counts by more than 90% with the monoclonal a

121 obstructive lung disease, symptom duration, neutrophil count, C-reactive protein level, lactate dehy

122 Peripheral neutrophil count, C-reactive protein, and proinflammator

123 openia, lung infection with grade 4 absolute neutrophil count, colon infection with grade 4 absolute

124 vement in lung function and a fall in sputum neutrophil count compared with subjects who continued to

125 8) congenics had significantly lower exudate neutrophil counts compared with DA.

126 atients had higher cerebrospinal fluid (CSF) neutrophil counts compared with non-TBM-IRIS patients (m

127 venous-arterial difference in F-actin-rimmed neutrophil counts completely accounted for sequestration

128 standard white blood cell count or absolute neutrophil count, continue to be investigated, but these

129 Likewise, age, asthma duration, and blood neutrophil counts correctly predicted 64% of sputum neut

130 Neutrophil count correlated with the molecular degree of

131 Median absolute neutrophil count decrease was 26%, and platelet decrease

132 mmon grade 3-4 adverse events reported were: neutrophil count decreased (26 [19%] of 134 in the chemo

133 nts vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and

134 - 2.3 log10 cfu/ml (p<0.0001), respectively; neutrophil count decreased by 0.4 +/- 0.6 log10 cells/ml

135 Neutrophil counts decreased by 0.31 x 10(9)/L (0.09-0.54

136 Neutrophil counts decreased, hemoglobin and low- and hig

137 in decreased abscess size, lower circulating neutrophil counts, decreased anemia, and improved surviv

138 ude mice are neutropenic or have near-normal neutrophil counts, depending on the prevailing intestina

139 Although pretreatment neutrophil count did not correlate with outcome, lower a

140 Total WBC and neutrophil counts did not change.

141 and body temperature, and systemic absolute neutrophil counts did not differ between groups.

142 de significant loci were associated with low neutrophil counts during clozapine treatment.

143 PA syndrome revealed significantly increased neutrophil counts, erythrocyte sedimentation rates, and

144 Reduced and elevated neutrophil counts, even within the normal range, are ass

145 eno levels, IgE levels, blood eosinophil and neutrophil counts, FEV1 percent predicted, and age are p

146 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]).

147 Total white blood cell and neutrophil counts following CLP were both significantly

148 ustained leukocytosis, due to an increase in neutrophils counts, follows.

149 nic neutropenia is defined as a low absolute neutrophil count for >6 months.

150 y predictive of time to recovery of absolute neutrophil count for both the fourth and fifth courses (

151 owed us to maintain stable circulating HoxB8 neutrophil counts for several days.

152 lood samples were drawn for determination of neutrophil counts for up to 28 d after injection.

153 Unlike the reduced neutrophil counts found in IL-17RA-deficient mice, neutr

154 ficant increase (two-fold, P < 0.05) in oral neutrophil counts found in patients with periodontitis c

155 electrocardiogram QT (five [2%]), decreased neutrophil count (four [2%]), anaemia, dyspnoea, hyponat

156 y outcomes included interleukin-8 levels and neutrophil counts from nasal wash, assessed at intake an

157 count, colon infection with grade 4 absolute neutrophil count, grade 4 changed mental status, and one

158 The median times to reach an absolute neutrophil count greater than 500/microL and platelet co

159 14 days, respectively, provided an absolute neutrophil count greater than 750x10(6)/L and a platelet

160 The median time to engraftment (absolute neutrophil count > 500/mm(3) and platelets 50 000/muL) w

161 g/dose, days 1-5 and day 15 through absolute neutrophil count > 500/uL]).

162 uate hepatic and renal function, an absolute neutrophil count > or = 500/microL and a platelet count

163 0/microL, 27% (95% CI, 18% to 36%); absolute neutrophil count >/=10000/microL, 18% (95% CI, 10% to 25

164 lower after CPX-351 (median days to absolute neutrophil count >/=1000: 36 vs 32; platelets >100 000:

165 ts, mortality was associated with higher CSF neutrophil counts (hazard ratio [HR], 1.10 per 10% incre

166 GSTM1) and the use of statins, obesity, high neutrophil counts, higher blood pressure, and older age.

167 A [SAA], vascular endothelial growth factor, neutrophil count, IL-1alpha, E-selectin, intercellular a

168 n drug-related adverse event was decrease in neutrophil count in 33% and 70% of the ALCL165 and ALCL2

169 dependently associated with peripheral blood neutrophil count in contacts of patients diagnosed with

170 utropenia in seven (14%) patients, decreased neutrophil count in three (6%) patients, infections in f

171 Decreased neutrophil counts in alveolar air spaces, despite normal

172 decrease in total protein concentration and neutrophil counts in alveolar fluid through bronchoalveo

173 increased absolute lymphocyte, monocyte, and neutrophil counts in blood to normal without significant

174 we examined patient outcomes and circulating neutrophil counts in cervical cancer patients treated wi

175 hibition of BAL fluid total, eosinophil, and neutrophil counts in HDM mouse asthma in vivo, as compar

176 he primary endpoint was percentage change in neutrophil counts in induced sputum 6 h after lipopolysa

177 -17RA) are all required to maintain baseline neutrophil counts in mice.

178 ansferred Rag1(-/-) or WT thymocytes correct neutrophil counts in neutropenic nude mice.

179 straints by tracking the dynamics of patient neutrophil counts in response to therapy.

180 L-17F could compensate and maintain baseline neutrophil counts in the absence of IL-17A.

181 lso used to identify changes associated with neutrophil counts in the airway.Measurements and Main Re

182 acterial counts in the lungs, with decreased neutrophil counts in the bronchoalveolar lavage fluid as

183 Bacterial and neutrophil counts in the lung were similar in control an

184 eutrophils and was associated with increased neutrophil counts in the sputum in response to ozone exp

185 nt to maintain the normal set point of blood neutrophil counts in vivo.

186 06; 39%) had increased monocyte, CD4(+), and neutrophil counts; increased C-reactive protein and inte

187 Stratification by eosinophil and neutrophil counts increases our understanding of asthma

188 cates that several BAL parameters, including neutrophil count, interleukin-8, alpha defensins and MMP

189 (4)/ml vs. 3.04 [2.82] x 10(4)/ml, p = 0.02) neutrophil counts, interleukin 8 (33.8 [189.8] vs. 16.9

190 Neutrophil counts less than 1.0 x 10(9) cells/L were obs

191 d as body temperature >/= 38.2 degrees C and neutrophil count < 0.5 x 10(9)/L on the same day of the

192 de pointes and severe neutropenia (absolute neutrophil count < or =500 cells/microL) were slightly h

193 erapy drug-induced agranulocytosis (absolute neutrophil count </=0.5 x 10(9)/L [</=500/muL]) and 5170

194 treatment discontinuation was required for a neutrophil count <0.5 x 10(9) cells/L.

195 ly 242 (8%) sustained an infection and had a neutrophil count <0.75 x 10(9) cells/L at any time while

196 Dose reduction was required for a neutrophil count <0.75 x 10(9) cells/L, and treatment di

197 estigator; 648 (21%) patients had at least 1 neutrophil count <0.75 x 10(9) cells/L, but only 242 (8%

198 The prevalence of neutropenia (neutrophil count <1.5 x 10(9) cells/L) was 4.5% among bl

199 ients with concomitant neutropenia (absolute neutrophil count <1000 cells/microL) and abdominal pain

200 d was used to identify neutropenia (absolute neutrophil count <1500 cells/mm(3)) at the time of port

201 A reduction in ascitic fluid neutrophil count <25% of pretreatment value was consider

202 solidation on chest radiograph, and absolute neutrophil count <5 x 109/L at presentation, which had a

203 bjects were those with neutropenia (absolute neutrophil count <500/muL) and proven/probable/presumed

204 Absolute neutrophil counts <1000/uL were noted in 12/106 (11%) ev

205 sfusion of RBCs stored for 10 days increased neutrophil counts, macrophage inflammatory protein-2 (MI

206 Benign reductions in neutrophil counts may be more common at certain ages and

207 Nine patients had increased neutrophil counts (median increase, 1350 per cubic milli

208 hereas age, FEV1 percent predicted, or blood neutrophil counts might predict sputum neutrophil percen

209 platelet count more than 75,000 x 10(6)/L, a neutrophil count more than 1,000 x 10(6)/L, and a creati

210 7 days from prior corticosteroids; absolute neutrophil count more than 1,500/microL (500/microL if d

211 The median time to absolute neutrophil count more than 500/microL after ASCR was 13

212 -) mice, resulting in very high platelet and neutrophil counts, more advanced myelofibrosis, and redu

213 Absolute neutrophil counts, motor function, Morris water maze per

214 ere decreased lymphocyte (n=3) and decreased neutrophil count (n=2); and grade 4 anaemia was reported

215 However, neither neutrophil count, Na(+) concentration, nor Na(+) : K(+)

216 s significantly associated with the absolute neutrophil count nadir (7/7 < 6/7 < 6/6, P =.02).

217 The time to the absolute neutrophil count nadir was shorter for the (90)Y-ibritum

218 e were significant predictors of ln(absolute neutrophil count nadir; r(2) = 0.51).

219 t 3 experienced significantly lower absolute neutrophil count nadirs than did younger groups (P = .02

220 BAL fluid neutrophil counts negatively and positively correlated w

221 ion decline was associated with increases in neutrophil counts, neutrophil elastase, and IL-1beta and

222 xpression in mixed chimeric mice depended on neutrophil count, not iNKT cell genotype.

223 The median time to achieve a neutrophil count of 0.5 x 10(9)/liter was 14 days (range

224 iatric patients with cancer with an absolute neutrophil count of 500/uL or greater is unclear.

225 .22; 95% CI, 0.17-0.30), as does an absolute neutrophil count of 6750/microL or lower (LR, 0.06; 95%

226 not significantly different at the absolute neutrophil count of less than 0.5 x 109 cells/L (P = 0.5

227 nts treated with tofacitinib had an absolute neutrophil count of less than 1500.

228 ith greater risk even among individuals with neutrophil counts of 3 to 4 versus 2 to 3 x 10(9)/l.

229 ence of enzyme replacement therapy, absolute neutrophil counts of patients with ADA deficiency vary i

230 atients with acute coronary syndrome, higher neutrophil count on admission and after revascularizatio

231 itive patients in the Oxford hospitals, mean neutrophil counts on diagnosis increased from 2003, peak

232 neutropenia are cyclic neutropenia, in which neutrophil counts oscillate with a 21-day frequency, and

233 In the immediate-initiation group, average neutrophil count over follow-up was 321 cells per muL hi

234 eroxia did not further increase chemokine or neutrophil counts over normoxia.

235 ite cell count was associated with increased neutrophil count (P < 0.001) and low-grade peritumoral i

236 s A and B), age (P < 0.01), mGPS (P < 0.01), neutrophil count (P < 0.05), and Klintrup criteria (P <

237 1), temperature (P<.05), pulse rate (P<.05), neutrophil count (P<.05), tumor necrosis factor- alpha l

238 an 84% decrease in the circulating absolute neutrophil count (P<0.001) before elastase perfusion.

239 ein concentration (p=0.0003) and in absolute neutrophil count (p=0.024) at 24 h after treatment than

240 tis and total leukocytes counts (p < 0.001), neutrophil counts (P <0.001) and hematocrit (HCT) levels

241 F showed a significant trend toward elevated neutrophil counts (P = 0.002) in BALF and increased mort

242 adjusted homocysteine levels (P<0.0001) and neutrophil counts (P<0.0001) than the no-progression gro

243 ere anaemia (nine [15%] of 62) and decreased neutrophil count, pancytopenia, and thrombocytopenia (tw

244 decreases from baseline in hemoglobin level, neutrophil count, platelet count, and weight compared wi

245 Maximum decreases in hemoglobin level, neutrophil count, platelet count, and weight during ther

246 n between grade 1 and grade 3 severity), CSF neutrophil count (r = 0.364 and P < .0001), and cytokine

247 lar lavage IL-8 (R(2) = 0.20, P = 0.004) and neutrophil count (R(2) = 0.21, P = 0.001).

248 ses intravenous immunoglobulins allowed full neutrophil count recovery.

249 (18)F-FLT changes preceded neutrophil count reductions.

250 sitive women and corresponded with increased neutrophil counts relative to BV-negative women.

251 re and treatment duration, only decreases in neutrophil count remained associated with virologic resp

252 Neutrophil counts remained unchanged.

253 so showed decreased lymphocyte and increased neutrophil counts, respectively.

254 Neutrophil counts returned to normal after cessation of

255 White blood cell and neutrophil counts, serum or plasma levels of fibrinogen,

256 Neutrophil counts should be carefully evaluated in prema

257 during the first 11 days (difference between neutrophil count slopes 0.34 x 10(9)/L/day; 95% CI 0.12-

258 risk factors and acute conditions affecting neutrophil counts (such as infections and cancer).

259 ent, group A had higher median leukocyte and neutrophil counts than group B (P < .001).

260 te its strong association with lower average neutrophil counts, the Duffy-null genotype was not assoc

261 re anaemia (seven [12%] of 59) and decreased neutrophil count (three [5%]); an additional six events

262 The median time to recovery of absolute neutrophil count to >/= 500 cells/microL was 11 days (ra

263 ic patients as 100% increase in the absolute neutrophil count to more than 5 x 10(8) cells per L, and

264 a, decreased lymphocyte count, and decreased neutrophil count (two [3%] each).

265 nt, AIDS, antiretroviral therapy, cirrhosis, neutrophil count, type of peg-IFN, and granulocyte colon

266 tality and biomarkers of inflammation (blood neutrophil count, urea, and creatinine concentrations) c

267 Androgen supplement can restore neutrophil counts via stabilizing AR in castrated mice,

268 The median presenting absolute neutrophil count was 100/muL.

269 arrow was enhanced, and the peripheral blood neutrophil count was also substantially elevated in thes

270 Lymphopenia was universal, but the neutrophil count was generally not affected.

271 receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 x 10(9)/L (or for

272 Compared with control, systemic absolute neutrophil count was increased more than ten-fold in gra

273 timulating factor was used when the absolute neutrophil count was less than 1,000/microL.

274 one from infection (although their absolute neutrophil count was normal), which was definitely relat

275 Time-updated neutrophil count was not associated with severe bacteria

276 Reduced sputum neutrophil count was observed among the 122 patients exa

277 The total white blood cell and neutrophil count was reduced from 7610 to 6980 cells/mic

278 Nadir lymphocyte count, not nadir neutrophil count, was independently associated with mode

279 This activation, like the drop in neutrophil count, was transient.

280 ctin, TNFalpha, and MPO and peripheral blood neutrophil count were higher in patients with RA than co

281 Median change in interleukin-8 levels and neutrophil counts were also not statistically significan

282 Blood neutrophil counts were elevated (4.8x), whereas lymphocy

283 ients of WT stem cells; however, circulating neutrophil counts were higher only in Rac2(-/-) recipien

284 s with the strongest relationships to sputum neutrophil counts were IL1R1 (standardized regression co

285 that 24 hours after infection macrophage and neutrophil counts were lower in the cornea of Lum(-/-) m

286 phil counts found in IL-17RA-deficient mice, neutrophil counts were mildly increased in IL-17A-defici

287 acterial loads, cytokine concentrations, and neutrophil counts were more likely to subsequently exper

288 differences in hemoglobin concentrations and neutrophil counts were no longer significant, whereas di

289 Lung edema, cytokines, and neutrophil counts were reduced after EVLP and further, s

290 Bacterial counts and neutrophil counts were significantly higher in the circu

291 As reported in the literature, sputum neutrophil counts were significantly increased in subjec

292 tney U test; P = .012) and day-14 (P = .025) neutrophil counts were significantly lower in patients r

293 Age, FEV1 percent predicted, and blood neutrophil counts were similarly unsatisfactory for the

294 Neutrophil counts were strongly associated with the inci

295 of depression, and female sex, but not nadir neutrophil count, were associated with moderate, severe,

296 end on the impact of treatment on peripheral neutrophil count, which has the potential to serve as an

297 ef review summarizes the regulation of blood neutrophil counts, which is in part controlled by G-CSF,

298 vel of 1,5-anhydroglucitol restored a normal neutrophil count, while administration of 1,5-anhydroglu

299 stigated associations of clinically recorded neutrophil counts with initial presentation for a range

300 to dosage-related decreases in the absolute neutrophil count, with a median decrease of 38% in the 4